Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial

被引：0
|
作者：
Schmid, P. [1 ]
McArthur, H. L. [2 ]
Cortes, J. [3 ,4 ]
Xu, B. [5 ]
Cardoso, F. [6 ]
Casalnuovo, M. L. [7 ]
Demirci, U. [8 ]
Freitas, R., Jr. [9 ]
Ghosh, J. [10 ]
Hegg, R. [11 ]
Iwata, H. [12 ]
Chuken, Y. A. Lopez [13 ]
Nechaeva, M. [14 ]
Robson, M. E. [15 ]
Villalobos Valencia, R. [16 ]
Lloyd, A. [17 ]
D'Cruz, C. [18 ]
Foxley, A. [18 ]
Park, Y. H. [19 ]
机构：
[1] Queen Mary Univ, Barts Canc Inst, Ctr Expt Canc Med, London, England
[2] UT Southwestern Med Ctr, Dallas, TX USA
[3] IBCC, Pangaea Grp, Barcelona, Spain
[4] IOB Madrid, Inst Oncol, Barcelona, Spain
[5] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
[6] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal
[7] CENIT Ctr Med Neurociencias, Buenos Aires, DF, Argentina
[8] Mem Ankara Hosp, Ankara, Turkiye
[9] Hosp Araujo Jorge, Goiania, Go, Brazil
[10] Tata Med Ctr, Kolkata, India
[11] Sao Paulo State Govt Womens Hlth Reference Ctr, Sao Paulo, Brazil
[12] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[13] ICAN Oncol Ctr, Monterrey, Mexico
[14] Arkhangelsk Reg Clin Oncol Dispensary, Arkhangelsk, Russia
[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[16] Consultorio Ctr Torre Med Dalinde, Oncol Med, Mexico City, DF, Mexico
[17] AstraZeneca, Oncol R&D, Cambridge, England
[18] AstraZeneca, Oncol R&D, Waltham, MA USA
[19] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.2257
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA19
引用
收藏
页码：1212 / 1213
页数：2
相关论文
共 50 条
  • [21] nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
    Yardley, D. A.
    Coleman, R.
    Conte, P.
    Cortes, J.
    Brufsky, A.
    Shtivelband, M.
    Young, R.
    Bengala, C.
    Ali, H.
    Eakel, J.
    Schneeweiss, A.
    de la Cruz-Merino, L.
    Wilks, S.
    O'Shaughnessy, J.
    Gluck, S.
    Li, H.
    Miller, J.
    Barton, D.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2018, 29 (08) : 1763 - 1770
  • [22] Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer
    Tredan, Olivier
    Campone, Mario
    Jassem, Jacek
    Vyzula, Rostislav
    Coudert, Bruno
    Pacilio, Carmen
    Prausova, Jana
    Hardy-Bessard, Anne-Claire
    Arance, Ana
    Mukhopadhyay, Pralay
    Aloe, Alessandra
    Roche, Henri
    CLINICAL BREAST CANCER, 2015, 15 (01) : 8 - 15
  • [23] Paclitaxel plus carboplatin versus paclitaxel plus epirubicin as first-line treatment for metastatic breast cancer: Efficacy and safety results of a randomized, phase III trial.
    Tong, Zhongsheng
    Li, Shufen
    Shi, Yehui
    Wang, Xu
    Wang, Chen
    Hao, Chunfang
    Wang, Xiaorui
    Meng, Wenjin
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Mechanisms of action and acquired resistance to atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer (mTNBC).
    Molinero, Luciana
    Emens, Leisha A.
    Goldstein, Leonard D.
    Abbas, Alexander R.
    Koeppen, Hartmut
    Rugo, Hope S.
    Adams, Sylvia
    Chui, Stephen Y.
    Schmid, Peter
    Loi, Sherene
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] A phase II randomized trial of gemcitabine plus cisplatin(GP) vs gemcitabine plus carboplatin (GC) as the first-line treatment for patients with metastatic triple-negative breast cancer
    Gong, Chengcheng
    Zhao, Yannan
    Wang, Leiping
    Cao, Jun
    Tao, Zhonghua
    Li, Ting
    Zhao, Mingchuan
    Miao, Haitao
    Jin, Juan
    Hu, Xichun
    Wang, Biyun
    CANCER RESEARCH, 2024, 84 (09)
  • [26] A Phase II randomized trial of pembrolizumab with carboplatin and gemcitabine for treatment of patients with metastatic triple-negative breast cancer (mTNBC)
    Obeid, E.
    Miller, K. D.
    Sparano, J. A.
    Blackwell, K.
    Goldstein, L. J.
    CANCER RESEARCH, 2017, 77
  • [27] Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).
    Page, David B.
    Chun, Brie
    Pucilowska, Joanna
    Kim, Isaac
    Sanchez, Katherine
    Redmond, William L.
    Sun, Zhaoyu
    Wu, Yaping
    Feryn, Alicia
    Martel, Maritza
    Abaya, Christina DiLauro
    Wadell, Dottie
    Mellinger, Staci L.
    Moxon, Nicole
    Urba, Walter John
    McAndrew, Philomena
    El-Masry, Maryliza
    Basho, Reva K.
    Conlin, Alison Katherine
    McArthur, Heather L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] tnAcity: A phase II/III trial of nab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC)
    Yardley, Denise A.
    Coleman, Robert E.
    Conte, Pierfranco
    O'Shaughnessy, Joyce
    Cortes, Javier
    Glueck, Stefan
    Brufsky, Adam
    Nabholtz, Jean-Marc A.
    Li, Li
    Miller, JulieAnn
    Barton, Debora
    Harbeck, Nadia
    CANCER RESEARCH, 2015, 75
  • [29] Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) plus paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
    Dent, R.
    Oliveira, M.
    Isakoff, S. J.
    Im, S-A.
    Espie, M.
    Blau, S.
    Tan, A. R.
    Saura, C.
    Wongchenko, M.
    Xu, N.
    Bradley, D.
    Reilly, S-J.
    Mani, A.
    Kim, S-B.
    ANNALS OF ONCOLOGY, 2020, 31 : S64 - S65
  • [30] Comparative effectiveness of nab-paclitaxel vs. paclitaxel m onotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice
    Luhn, T.
    Chui, S.
    Hsieh, A.
    Yi, J.
    Mecke, A.
    Bajaj, P.
    Hasnain, W.
    Falgas, A.
    Ton, T. G. N.
    Kurian, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 101 - 101
12345